Prognostic value of alternative lengthening of telomeres-associated biomarkers in uterine sarcoma and uterine carcinosarcoma

International Journal of Gynecological Cancer

Volumn 22, Issue 3, 2012, Pages 434-441

  Lee, Yoo Kyung ^a,b   Park, Noh Hyun ^b   Lee, Hyunsook ^a  

^a Institute of Molecular Biology and Genetics   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

ALT associated promyelocytic leukemia body; Alternative lengthening of telomeres; Prognostic factor; Uterine carcinosarcoma; Uterine sarcoma

Indexed keywords

GENOMIC DNA; TELOMERASE REVERSE TRANSCRIPTASE;

ADULT; AGED; ALT ASSOCIATED PROMYELOCYTIC LEUKEMIA BODY; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CANCER TISSUE; CARCINOSARCOMA; CELL ORGANELLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MITOSIS INDEX; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TELOMERE ALTERNATIVE LENGTHENING; TELOMERE HOMEOSTASIS; UTERUS CARCINOMA; UTERUS CARCINOSARCOMA; UTERUS SARCOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOSARCOMA; FEMALE; HUMANS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SARCOMA; TELOMERASE; TELOMERE HOMEOSTASIS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS; YOUNG ADULT;

EID: 84863256085     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31823ca017     Document Type: Article

References (25)

1. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer. 2002;2:331-341. (Pubitemid 37328946)
2. Blasco MA. Telomere length, stem cells and aging. Nat Chem Biol. 2007;3:640-649. (Pubitemid 47417712)
3. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997;33:787-791.
4. Hakin-Smith V, Jellinek DA, Levy D, et al. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet. 2003;361:836-838. (Pubitemid 36331849)
5. Henson JD, Hannay JA, McCarthy SW, et al. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res. 2005;11: 217-225. (Pubitemid 40075798)
6. Costa A, Daidone MG, Daprai L, et al. Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res. 2006;66: 8918-8924. (Pubitemid 44449211)
7. Johnson JE, Varkonyi RJ, Schwalm J, et al. Multiple mechanisms of telomere maintenance exist in liposarcomas. Clin Cancer Res. 2005;11:5347-5355. (Pubitemid 41060807)
8. Kammori M, Kanauchi H, Nakamura K, et al. Demonstration of human telomerase reverse transcriptase in human colorectal carcinomas by in situ hybridization. Int J Oncol. 2002;20:15-21.
9. Henson JD, Neumann AA, Yeager TR, et al. Alternative lengthening of telomeres in mammalian cells. Oncogene. 2002;21:598-610. (Pubitemid 34146260)
10. Serakinci N, Hoare SF, Kassem M, et al. Telomerase promoter reprogramming and interaction with general transcription factors in the human mesenchymal stem cell. Regen Med. 2006;1:125-131.
11. Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993;71:1702-1709. (Pubitemid 23056094)
12. Yamada SD, Burger RA, Brewster WR, et al. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer. 2000;88:2782-2786. (Pubitemid 30417939)
13. Abeler VM, Royne O, Thoresen S, et al. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology. 2009;54:355-364.
14. Giuntoli RL 2nd, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol. 2003;89:460-469. (Pubitemid 36687793)
15. Bryan TM, Englezou A, Gupta J, et al. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J. 1995;14:4240-4248.
16. Cesare AJ, Griffith JD. Telomeric DNA in ALT cells is characterized by free telomeric circles and heterogeneous t-loops. Mol Cell Biol. 2004;24:9948-9957. (Pubitemid 39458820)
17. Yeager TR, Neumann AA, Englezou A, et al. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res. 1999;59:4175-4179. (Pubitemid 29418720)
18. Nabetani A, Ishikawa F. Unusual telomeric DNAs in human telomerase-negative immortalized cells. Mol Cell Biol. 2009;29:703-713.
19. Wang RC, Smogorzewska A, de Lange T. Homologous recombination generates T-loop-sized deletions at human telomeres. Cell. 2004;119:355-368. (Pubitemid 39423838)
20. Henson JD, Cao Y, Huschtscha LI, et al. DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. Nat Biotechnol. 2009;27:1181-1185.
21. Wu YL, Dudognon C, Nguyen E, et al. Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths. J Cell Sci. 2006;119:2797-2806. (Pubitemid 44184016)
22. George E, Lillemoe TJ, Twiggs LB, et al. Malignant mixed mullerian tumor versus high-grade endometrial carcinoma and aggressive variants of endometrial carcinoma: a comparative analysis of survival. Int J Gynecol Pathol. 1995;14:39-44.
23. Stewart SA, Hahn WC. Prospects for anti-neoplastic therapies based on telomere biology. Curr Cancer Drug Targets. 2002;2:1-17. (Pubitemid 34627375)
24. Ulaner GA, Huang HY, Otero J, et al. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res. 2003;63:1759-1763. (Pubitemid 36469314)
25. Chang KL, Crabtree GS, Lim-Tan SK, et al. Primary uterine endometrial stromal neoplasms. A clinicopathologic study of 117 cases. Am J Surg Pathol. 1990;14:415-438. (Pubitemid 20140662)